{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-26-000015","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-08-06T20:06:04+00:00","discovered_at":"2026-08-06T20:08:02.430271+00:00","generated_at":"2026-08-06T20:08:49.856114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin Q2 revenue up 20% to $990M; GAAP EPS $0.23 vs $1.23; raises VOXZOGO guidance","bullets":["Total revenues $990M (+20% YoY); GAAP net income $45M ($0.23 diluted EPS) vs $241M ($1.23) in Q2 2025.","Non-GAAP income $236M ($1.20 diluted EPS) vs $282M ($1.44) in prior year, down 16%.","VOXZOGO revenue $253M (+14% YoY); full-year guidance raised to at least $1B.","Amicus acquisition closed April 27; cost synergies of ~$280M GAAP / ~$220M non-GAAP expected fully realized by 2028.","Pipeline: sNDA submitted for VOXZOGO in hypochondroplasia; BMN 401 discontinued after Phase 3 miss."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-26-000015","json":"https://secwatch.observer/filing/0001048477-26-000015.json","markdown":"https://secwatch.observer/filing/0001048477-26-000015.md","text":"https://secwatch.observer/filing/0001048477-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/0001048477-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/bmrn-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:08:49.856114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}